AAM Warns Of Dangerous Precedent In Vascepa 'Skinny Label' Case
Files Amicus Brief In Support Of Hikma Over Amarin Induced Infringement Claims
By allowing Amarin’s allegation of induced infringement against Hikma over its generic version of Vascepa to proceed, a US court is jeopardizing the ‘skinny label’ system that allows generics to carve out patented indications from their labels under the Hatch-Waxman framework, according to the AAM.
